Literature DB >> 7241183

Pharmacokinetics of epsilon-aminocaproic acid during peritoneal dialysis.

S S Fish, S Pancorbo, R Berkseth.   

Abstract

Two patients requiring peritoneal dialysis were treated with epsilon-aminocaproic acid (EACA), an antifibrinolytic agent. Samples of serum and dialysate were assayed for EACA concentrations. Total body clearance, dialysis clearance, EACA half-life, and volume of distribution of EACA were calculated. Total body clearance of EACA was 26 ml/min, which is 25% of the drug clearance in patients with normal renal function. Our results suggest that patients undergoing peritoneal dialysis should receive 25% of the usual recommended dose of EACA. Dialysis clearance accounted for only 58% of total body clearance, suggesting an alternative route of elimination of EACA.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7241183     DOI: 10.3171/jns.1981.54.6.0736

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

1.  Population pharmacokinetics of ϵ-aminocaproic acid in adolescents undergoing posterior spinal fusion surgery.

Authors:  P A Stricker; M R Gastonguay; D Singh; J E Fiadjoe; E M Sussman; E Y Pruitt; T K Goebel; A F Zuppa
Journal:  Br J Anaesth       Date:  2015-01-13       Impact factor: 9.166

Review 2.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

3.  Population pharmacokinetics of epsilon-aminocaproic acid in infants undergoing craniofacial reconstruction surgery.

Authors:  P A Stricker; A F Zuppa; J E Fiadjoe; L G Maxwell; E M Sussman; E Y Pruitt; T K Goebel; M R Gastonguay; J A Taylor; S P Bartlett; M S Schreiner
Journal:  Br J Anaesth       Date:  2013-01-25       Impact factor: 9.166

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.